Retinoic acid-primed human dendritic cells inhibit Th9 cells and induce Th1/Th17 cell differentiation

All-trans-retinoic acid plays a central role in mucosal immunity, where it promotes its synthesis by upregulating CD103 expression on dendritic cells, induces gut tropic (alpha 4 beta 7(+) and CCR9(+)) T cells, and inhibits Th1/Th17 differentiation. Recently, murine studies have highlighted the proinflammatory role of retinoic acid in maintaining inflammation under a variety of pathologic conditions. However, as a result of limited human data, we investigated the effect of retinoic acid on human dendritic cells and CD4(+) T cell responses in the presence of polarizing (Th1/Th9/Th17) and inflammatory (LPS-induced dendritic cells) conditions. We report a novel role of retinoic acid in an inflammatory setup, where retinoic acid-primed dendritic cells (retinoic acid-monocyte-derived dendritic cells) up-regulated CCR9(+)T cells, which were observed to express high levels of IFN-gamma in the presence of Th1/Th17 conditions. Retinoic acid-monocytederived dendritic cells, under Th17 conditions, also favored the induction of IL-17(+) T cells. Furthermore, in the presence of TGF-beta 1 and IL-4, retinoic acid-monocyte-derived dendritic cells inhibited IL-9 and induced IFN-gamma expression on T cells. Experiments with naive CD4(+) T cells, activated in the presence of Th1/Th17 conditions and absence of DCs, indicated that retinoic acid inhibited IFN-gamma and IL-17 expression on T cells. These data revealed that in the face of inflammatory conditions, retinoic acid, in contrast from its anti-inflammatory role, could maintain or aggravate the intestinal inflammation.